Introduction {#s02}
============

In 2003 we highlighted aspects of phenotypic overlap between the rare Mendelian encephalopathy Aicardi-Goutières syndrome (AGS), the complex autoimmune disease systemic lupus erythematosus (SLE), and certain congenital viral infections, including transplacentally acquired human immunodeficiency virus (HIV-1), and postulated that this overlap might result from the common pathological feature of an up-regulation of interferon α activity ([@bib25]). The subsequent partial dissection of the genetic basis of AGS ([@bib26],[@bib27]; [@bib77]), the molecular definition of a monogenic form of SLE associated with up-regulated type I interferon ([@bib14]; [@bib58]), and the developing understanding of a primary link between nucleic acid metabolism and interferon induction led to the proposition, in 2011, of the grouping of Mendelian disorders associated with an up-regulation of type I interferon signaling as a novel set of human inborn errors of immunity, in which such constitutive up-regulation is central to pathogenesis ([@bib22]). In 2015, a framework was proposed for the consideration of the pathogenesis of this group of diseases ([@bib23]; [@bib24]), which can be viewed as analogous to previously described single-gene defects in immune signaling pathways leading to primary immunodeficiency ([@bib18]) and monogenic autoinflammation ([@bib52]).

At the outset, it is important to state that, as strictly defined, the central tenet of the type I interferonopathy concept remains unproven; i.e., definitive evidence that pathology is determined by an up-regulation of type I interferon signaling is lacking. Indeed, it will not be until we have therapeutic agents that specifically target type I interferon signaling, and use them in putative type I interferonopathy patients, that the contribution of type I interferon to clinical phenotype will become clear. Simply put, at this time, it is still possible that the finding of up-regulated type I interferon signaling in certain phenotypes represents an association rather than a pathologically causal relationship. That being said, as we argue below, the observation of phenotypic overlap, the elucidation of shared pathomechanisms through human genetics, in vitro and in vivo experimentation, and the first results of early treatment trials all give support to the scientific validity of the type I interferonopathy grouping.

Because this is a field in its infancy, it is necessary to avoid being overly didactic. Thus, except in a few cases, most notably perhaps disease related to mutations in *TREX1* and *RNASEH2B*, it is important to acknowledge that the true clinical spectrum and frequency of features associated with particular genotypes is likely not known. This point is well illustrated by the expansion of the phenotype associated with mutations in *TMEM173* in a period of a little over two years, now spanning early-onset systemic inflammation with mutilating skin lesions and lethal pulmonary inflammation ([@bib51]; [@bib61]), through to "idiopathic" lung fibrosis ([@bib20]; [@bib73]) and isolated chilblain lupus inherited stably across several generations ([@bib55]). Similar uncertainty exists in regard to questions central to disease pathogenesis, e.g., the exact source and nature of the endogenous ligands considered to induce a type I interferon response in certain of the type I interferonopathies. As such, the aim here is to draw out general themes relating to phenotype and pathology, fully expecting that our understanding of detail will change over the short to medium term.

Which diseases should be considered as type I interferonopathies? {#s03}
=================================================================

Given that the acid test of response to anti-interferon therapy is not yet available, here we base our inclusion of distinct monogenic disorders as type I interferonopathies on evidence indicating a persistent up-regulation of type I interferon signaling, assessed by measuring the expression of interferon-stimulated genes (ISGs) and/or in vivo (animal)/ex vivo/in vitro experimental evidence. This group thus comprises 18 genotypes in which we consider that the link to enhanced interferon signaling is established ([Table 1](#tbl1){ref-type="table"} and [Fig. 1](#fig1){ref-type="fig"}). The somewhat imprecise nature of these criteria means that we do not include, for example, gain-of-function mutations in *STAT1*, although it may be that future studies will demonstrate a functional relationship of ISG production to phenotype. For similar reasons, we exclude discussion of DNASE1L3, chronic granulomatous disease, prolidase deficiency, and some early components of the complement cascade, all of which are associated with an increased risk of SLE, so that one might predict an up-regulation of type I interferon signaling but where the point rests unproven. Other diseases that may also come to be considered in this grouping, but where we feel that the evidence currently remains uncertain, are those caused by mutations in *CECR1* ([@bib11]; [@bib92]), *TRNT1* ([@bib37]), and *RNASET2* ([@bib90]).

###### Genotypes considered as type I interferonopathies in this manuscript, with protein function, link to interferon signaling, proposed molecular mechanism, and currently recognized associated clinical phenotypes

  Gene         Protein function                                     Sensing/activation pathway related to type I interferon signaling   Mutation effect                        Major patient phenotypes
  ------------ ---------------------------------------------------- ------------------------------------------------------------------- -------------------------------------- --------------------------
  *TREX1*      Deoxyribonuclease                                    Cytosolic DNA                                                       LOF (recessive or dominant-negative)   AGS, FCL, SLE
  *SAMHD1*     Control of dNTP pool (±nuclease)                     Cytosolic DNA (±cytosolic RNA)                                      LOF (recessive)                        AGS, FCL, CVD
  *TMEM173*    Transduction of cytosolic type I interferon signal   Cytosolic DNA (±cytosolic RNA)                                      GOF (dominant)                         SAVI, FCL
  *RNASEH2A*   Ribonuclease                                         Cytosolic RNA:DNA hybrids                                           LOF (recessive)                        AGS
  *RNASEH2B*   Ribonuclease                                         Cytosolic RNA:DNA hybrids                                           LOF (recessive)                        AGS, SP
  *RNASEH2C*   Ribonuclease                                         Cytosolic RNA:DNA hybrids                                           LOF (recessive)                        AGS
  *POLA1*      Polymerase                                           Cytosolic RNA:DNA hybrids                                           X-linked recessive                     XLPDR
  *ADAR1*      RNA editing                                          Cytosolic RNA                                                       LOF (recessive or dominant-negative)   AGS, DSH, BSN, SP
  *IFIH1*      dsRNA sensor                                         Cytosolic RNA                                                       GOF (dominant)                         AGS, SP, SMS
  *RIG-I*      dsRNA sensor                                         Cytosolic RNA                                                       GOF (dominant)                         Atypical SMS
  *SKIV2L*     RNA helicase                                         Cytosolic RNA                                                       LOF (recessive)                        THES
  *UPS18*      Inhibition of ISG transcription                      IFNAR1 signaling                                                    LOF (recessive)                        pseudo-TORCH
  *ISG15*      Inhibition of ISG transcription                      IFNAR1 signaling                                                    LOF (recessive)                        MSMD, ICC
  *PSMB8*      Proteasome                                           Unknown                                                             LOF (recessive)                        PRAAS
  *PSMB4*      Proteasome                                           Unknown                                                             LOF (recessive)                        PRAAS
  *PSMA3*      Proteasome                                           Unknown                                                             LOF (recessive)                        PRAAS
  *ACP5*       Phosphatase activity related to osteopontin          Unknown                                                             LOF (recessive)                        SPENCD, SLE, cytopenias
  *C1q*        Alternative complement pathway activity              Unknown                                                             LOF (recessive)                        SLE

BSN, bilateral striatal necrosis; CVD, cerebrovascular disease; DSH, dyschromatosis symmetrica hereditaria; FCL, familial chilblain lupus; GOF, gain-of-function; ICC, intracranial calcification; LOF, loss-of-function; MSMD, Mendelian susceptibility to mycobacterial disease; PRAAS, proteasome-associated autoinflammatory syndrome; SAVI, STING-associated vasculopathy with onset in infancy; SMS, Singleton-Merten syndrome; SP, spastic paraparesis; SPENCD, spondyloenchondrodysplasia; XLPDR, X-linked reticulate pigmentary disorder.

![**Type I interferon signaling and type I interferonopathies as currently assigned.** Diseases considered as monogenic interferonopathies are represented by blue boxes. This schema alludes to at least seven possible cellular mechanisms resulting in sustained activation of interferon signaling caused by the following: (1) loss-of-function mutations leading to increased cytosolic DNA (TREX1 \[[@bib88]\] and SAMHD1 \[[@bib10]; [@bib75]\]) or RNA/DNA hybrid (RNASEH2A, RNASEH2B and RNASEH2C, POLA1) sensing ([@bib46]; [@bib64]; [@bib87]); (2) loss-of-function mutations leading to a defect in RNA editing and abnormal sensing of self--nucleic acid RNA species in the cytosol (ADAR1 \[[@bib60]; [@bib72]\]); (3) gain-of-function mutations leading to constitutive activation of cytosolic interferon signaling pathways/increased sensitivity to cytosolic nucleic acid ligands (MDA5 \[[@bib80]\], RIG-I \[[@bib50]\], and STING \[[@bib61]\]); (4) loss-of-function mutations leading to aberrant RNA signaling via MAVS caused by a disturbance of the unfolded protein response (SKIV2L \[[@bib36]\]); (5) loss-of-function mutations in molecules responsible for limiting interferon receptor (IFNAR1/2) signaling leading to uncontrolled ISG production (USP18 \[[@bib66]\] and ISG15 \[[@bib96]\]); (6) proteasomal dysfunction leading to increased interferon signaling through an unknown mechanism (PSMA3, PSMB4, and PSMB8 \[[@bib13]\]; we do not include the so-far single-published mutations in PSMB9 and POMP); and (7) loss-of-function mutations in TRAP/*ACP5* ([@bib14]; [@bib58]) and C1q ([@bib63]; [@bib83]) where we consider the mechanisms leading to type I interferon signaling are yet to be fully clarified (we do not include mutations in other molecules of the complement pathway as a clear demonstration of enhanced interferon signaling has not been established).](JEM_20161596_Fig1){#fig1}

It is of course the case that dysfunction of certain proteins can have more than one biological consequence. For example, in the context of the putative type I interferonopathies, ADAR1 has both an interferon-related and a distinct developmental (MDA5/MAVS independent) function ([@bib72]). Of possible note also, *Rnaseh2b* knockout confers embryonic lethality in the mouse ([@bib46]; [@bib76]), in the absence of the induction of an interferon response, which is seen in the corresponding hypomorphic model ([@bib64]; [@bib74]). Whether or not this difference reflects distinct biological roles of the RNase H2 complex or the timing/degree of a shared disturbance of ribonucleotide excision repair remains unknown. The situation appears clearer with respect to mutations in *SKIV2L* causing tricho-hepato-enteric syndrome (THES). Here, there is a markedly elevated ISG expression and a proven link to interferon signaling via a disturbance of the unfolded protein response ([@bib36]). However, the same disease phenotype can be caused by mutations in *TTC37*, where no such interferon signature is present, and where, in contrast to SKIV2L, in vitro assays do not suggest a role in interferon signaling. These data lead to the conclusion that most of the features of THES are the consequence of a loss of cytosolic RNA exosome function in RNA turnover, rather than an aberrant interferon response that is apparently specific to SKIV2L deficiency.

It is interesting to view the aforementioned observations in regards to the potential efficacy of future anti-interferon therapy. Thus, the involvement/dysfunction of noninterferon-related disease pathways in a phenotype would variably limit the efficacy of such treatment. On this basis then, one can conceptualize the existence of more "pure" interferonopathies, where anti-interferon therapy would be expected to have the greatest benefit, and "mixed" phenotypes, where such therapies would be of more limited or, indeed, no utility.

Is it appropriate to use the term type I interferonopathies (I)? {#s04}
================================================================

In 1957 Isaacs and Lindenmann described a soluble factor that protects cells from viral infection, which agent, in consideration of its antiviral interfering properties, they termed interferon ([@bib47]; [@bib48]). We now know that multiple species of type I interferon exist, with this heterogeneity arising from the presence of 13 functional α genes and single genes for interferon β, ε, κ, and ω. Despite almost 60 years of active research, an understanding of the role of these different interferon species has been hampered by the inability to directly measure type I interferon protein in biological samples using available ELISAs. Correspondingly, type I interferon mRNA is usually unrecordable in peripheral blood from healthy individuals, even after vaccination ([@bib86]), or in patients with putative type I interferonopathies. Such low levels of circulating interferons likely reflect the very high biological potency of these cytokines, with most cell types expressing a type I interferon receptor. As a practical work-around of this problem, researchers have made extensive use of the measurement of the mRNA of genes that are induced by interferon (ISGs), thus effectively capturing an amplified signal consequent upon the interferon stimulus ([@bib8]; [@bib12]). Indeed, we have shown that the measurement of six ISGs represents a powerful screening tool for the identification of several of the putative type I interferonopathies ([@bib79]).

The repertoire of ISGs produced in response to type I, II, or III interferons show considerable overlap, begging the legitimate question as to whether or not it is type I interferons that are relevant---solely, partially, or not at all---to the up-regulation of ISGs seen in the diseases discussed here. At least in the context of AGS, data have been published to indicate that interferon activity in patient material, as measured using an antiviral cytopathic protection assay, can be neutralized by antiserum against interferon α but not β ([@bib59]; [@bib79]). Furthermore, levels of interferon γ were below the detectable range of a sensitive ELISA, and thus possibly inconsistent with the degree of interferon activity recorded in certain of these samples. Although these data are important, the field awaits the availability of high-sensitivity protein assays allowing the quantification of discrete interferons, at least in circulation. Such a tool could be usefully combined with measures of ISG production and/or interferon activity, thus capturing the relationship between the inducing (protein) signal and the response (ISGs/antiviral activity) to that signal and thereby enabling an exploration of interferon signaling dynamics. As we have previously noted, the absence of a reliable, high-throughput measure of type I interferon in routine medical practice goes some way to explaining why the concept of the type I interferonopathies as a discrete pathological grouping has only recently been mooted.

Is it appropriate to use the term type I interferonopathies (II)? {#s05}
=================================================================

Returning to an earlier point, the question arises as to whether the enhanced interferon signaling identified in the proposed type I interferonopathies represents a true pathological factor or simply a disease biomarker. The answer to this question is of fundamental importance because the former possibility implies the potential utility of therapeutic approaches targeting interferon up- and downstream signaling.

Considering clinically derived observations, the fact that, in its classical form ([@bib3]), AGS is such a remarkable Mendelian mimic of certain congenital infections provides circumstantial support to the up-regulation of interferon signaling, recorded in both situations, representing a common pathogenic link. Second, numerous reports describe the occurrence, after treatment with interferon, of features such as digital vasculitis ([@bib5]), SLE ([@bib81]), and glaucoma ([@bib57]), which are also seen in the putative type I interferonopathies. As a final point, and as discussed in more detail below, the recognition of a shared set of clinical signs, most particularly intracranial calcification and skin inflammation, across several of these genotypes is further evidence in favor of pathogenic overlap.

Experimental evidence also supports a primary role for interferon in the diseases discussed here. Likely indicative of intrathecal synthesis, levels of interferon activity in the cerebrospinal fluid of AGS patients are consistently higher than in matched serum samples ([@bib29]). Undoubtedly, interferon is a neurotoxin, and experiments undertaken in mice demonstrate that overexpression of interferon in the central nervous system (CNS) results in neuropathology reminiscent of that seen in certain type I interferonopathies ([@bib4]; [@bib17]; [@bib54]). Relevant crosses in other mouse models, in particular double knockouts involving the type I interferon receptor, provide unequivocal evidence of the importance of type I interferon signaling in these settings ([@bib88]; [@bib42]). Furthermore, given that cytosolic nucleic acid recognition represents a principal trigger for the induction of type I interferon, it is of note that 11 of the 18 diseases discussed here involve mutations in genes known to play a role in nucleic acid metabolism/signaling. We highlight particularly that gain-of-function mutations in MDA5 (*IFIH1*), RIG-I (*DDX58*), and STING (*TMEM173*), essential components of cytosolic nucleic acid signaling to a type I interferon response, and biallelic loss-of-function mutations in USP18 or ISG15, both involved in the negative regulation of ISG expression, are all associated with currently recognized type I interferonopathy phenotypes.

Phenotypic overlap and differences, variable expression, and nonpenetrance {#s06}
==========================================================================

As touched on above, there is a striking overlap of clinical features, particularly the involvement of the CNS and the skin, across several of the disorders classified here as type interferonopathies ([Fig. 2](#fig2){ref-type="fig"}). Indeed, we would highlight the value of searching for the presence of intracranial calcification, most easily appreciated on computed tomography, even in the absence of overt neurological signs, and the presence of vasculitic/chilblain-like skin lesions as highly useful clinical markers of this disease grouping. At the same time, major phenotypic differences exist between certain of these genotypes. Thus, the severe lung disease that frequently accompanies mutations in *TMEM173* has not been reported in the context of other putative type I interferonopathies, whereas the essentially distinct complex diseases SLE, systemic sclerosis, and dermatomyositis all correlate with the presence of a type I interferon signature. Such observations apparently challenge the suggestion of the primacy of interferon as a shared pathogenic molecule. While acknowledging this point, we have already highlighted that dysfunction of certain proteins can have more than one biological consequence, which might explain different phenotypic characteristics across genotypes. Furthermore, distinct expression patterns of relevant disease-associated proteins, their protein partners, interferon-inducing signaling components, and proteins involved in alternative ("redundant") signaling pathways according to the gene/protein mutated might also be relevant. Finally, we draw attention to the possible importance of the timing of a putative interferon-related insult. Perhaps instructive here, similar to AGS, congenital HIV-1 infection is characterized by intracranial calcification, white matter abnormalities, cerebral atrophy, and high levels of interferon α ([@bib53]; [@bib56]; [@bib33]), whereas these radiological signs are not seen with postnatally acquired HIV-1 infections, suggesting that the developing brain is specifically susceptible to intrauterine viral exposure/the host interferon response ([@bib89]).

![**Specific and overlapping features of monogenic type I interferonopathies.** In the broadest sense, CNS and skin disease are the most common features of the type I interferonopathies. Discrete neurological phenotypes associated with mutations in AGS-associated genes include "nonsyndromic" spastic paraparesis (*RNASEH2B*, *ADAR1*, and *IFIH1* \[[@bib28]\]) and bilateral striatal necrosis (*ADAR1* \[[@bib62]\]). Glaucoma is a common feature of AGS ([@bib29]) and is also seen in the Singleton-Merton syndrome phenotype associated with gain-of-function mutations in *IFIH1* ([@bib16]; [@bib82]) and *DDX58* (RIG-I \[[@bib50]\]). SLE (lupus) is most frequently associated with mutations in *ACP5* ([@bib7]; [@bib15]) and *C1q* ([@bib63]; [@bib83]). Malignancy has only been reported in the context of *SAMHD1* ([@bib21]; [@bib65]). Lung inflammation is so far restricted to patients with mutations in *TMEM173* (STING; [@bib61]; [@bib20]; [@bib73]). The phenotypes associated with mutations in *POLA1* and *SKIV2L* appear distinct.](JEM_20161596_Fig2){#fig2}

It is also pertinent to acknowledge the variable expression, and even nonpenetrance, seen in certain type I interferonopathies, particularly relating to the recurrent dominant-negative mutations in *ADAR1* (Gly1007Arg; [@bib78]; [@bib62]) and *TREX1* (p.Asp18Asn; [@bib1]) and dominant gain-of-function mutations in *IFIH1* ([@bib80]) and *TMEM173* ([@bib51]). To explain these observations, we need to invoke differential exposure to environmental triggers such as infection or the effect of genetic modifiers. Indeed, considering a putative role of physical stressors, note should be made of the cold dependency of the skin lesions seen in the type I interferonopathies and of a striking temporal relationship between the onset of *ADAR1*-related bilateral striatal necrosis and preceding infection ([@bib62]). Whether vaccination represents a disease trigger is an important, and currently unanswered, question. Meanwhile, the possibility of a "cumulative" genetic burden contributing to cellular pathology is notable in light of recently published data on the group of type I interferonopathies caused by loss-of-function mutations in proteasome subunits ([@bib13]).

As an allied but distinct point, the identification of dominant gain-of-function mutations in *IFIH1* has highlighted the possibility of clinical nonpenetrance into old age in the presence of life-long, marked overexpression of ISGs ([@bib80]). This situation is reminiscent of a mouse model where transgenic expression of a picornavirus RNA-dependent RNA polymerase (RdRP) leads to a dramatic up-regulation of ISG stimulation and profound viral resistance via an MDA5/MAVS-dependent pathway, but where the mice are entirely healthy ([@bib70]). The contrast with mouse models also showing type I interferon up-regulation, but demonstrating a clear link between interferon expression and phenotype, might relate to the involvement of other inflammatory cytokines in the latter cases. A further possibility is that the constitutively augmented RdRP-induced antiviral network is balanced by up-regulation of type I interferon negative regulators such as Usp18, and which effect might be tissue specific. Interestingly, polymorphisms across *TMEM173* ([@bib95]) and *IFIH1* ([@bib85]), some of which occur at relatively high population frequencies, can be associated with marked differential interferon induction in vitro. It may be that such genetic variation reflects an evolutionary balance between the response to infection and the risk of inflammatory disease ([@bib84]). The observation of heritable high interferon production in certain families demonstrating an increased risk of SLE possibly represents a further piece of evidence in favor of this hypothesis ([@bib68]).

Autoinflammation or autoimmunity? {#s07}
=================================

At least in regard to AGS, different authors variably refer to the associated pathology as either autoimmune or autoinflammatory in basis, with the use of the latter term being particularly favored where the emphasis is being placed on the link to SLE. A suggested definition of autoinflammation relates to disorders characterized by abnormally increased inflammation, mediated predominantly by cells and molecules of the innate immune system, with a significant host predisposition ([@bib52]). Thus, according to the schema outlined above, we propose that, as a group, the type I interferonopathies can reasonably be considered as autoinflammatory in origin, with "spill-over" into autoimmunity in some cases. Having made this point, we would add that rather than being overly concerned by questions of classification, the cornerstone of the type I interferonopathy concept, as envisaged here, relates to a primary role of type I interferon in disease pathogenesis, irrespective of the relative involvement of innate/adaptive immune components.

There is a clear association of certain type I interferonopathies with autoimmunity, and SLE in particular, as indicated by the co-occurrence of such rare phenotypes (e.g., [@bib32]; [@bib34]; [@bib44]; [@bib93]). Furthermore, a broad spectrum of autoantibodies has been observed in patients with AGS ([@bib30]; [@bib96]; [@bib19]), albeit distinct from other autoimmune diseases. At the same time, it is striking that monogenic interferon-related inflammation, as so-far defined, is most frequently unaccompanied by frank autoimmunity ([@bib29]), so that it is difficult to know if these autoantibodies are pathologically relevant or represent an epiphenomenon consequent upon a more general immune dysregulation. The (inconsistent) link to overt autoimmunity in certain type I interferonopathies might reflect variable engagement of the adaptive immune system secondary to an initial, interferon-associated, innate immune disturbance. Having said this, in contrast to AGS and STING-related disease for example, there is a remarkably high risk of autoimmune cytopenias and early-onset SLE in the context of mutations in *ACP5* ([@bib14], [@bib15]; [@bib58]) and complement components ([@bib91]), suggesting that these encoded proteins have particular roles more closely aligned to the maintenance of self-tolerance.

The acceptance of the type I interferonopathies as autoinflammatory disorders implies that autoinflammation can be considered as both interferon and noninterferon related. From a clinical perspective, it is clear that certain type I interferonopathies can present as "classical" autoinflammatory phenotypes, demonstrating recurrent fevers and/or organ-specific involvement with elevated markers of systemic inflammation in the absence of autoimmunity and underlying infection. At the same time, most patients conforming to this clinical description that we have tested show no evidence of enhanced type I interferon signaling (unpublished data), lending support to the specificity of type I interferon--induced gene transcript measurement as a screening tool. This distinction is likely also reflected in the observation that noninterferon-related autoinflammation is not normally associated with a risk of lupus.

Cellular pathology and therapeutic approaches {#s08}
=============================================

The cellular pathology of the type I interferonopathies is associated with a diversity of mechanisms currently encompassing nucleic acid signaling in the broadest sense, proteasomal dysfunction and the unfolded protein response. Mouse work has been particularly instructive in defining the signaling pathways involved in several putative type I interferonopathies, so that we can now think of 11 of these genotypes as being transduced via cytosolic DNA (3), RNA (4) or RNA:DNA (4) hybrid sensing. Most type I interferonopathy genotypes relate to loss of protein function, whereas mutations in MDA5, RIG-I, and STING are associated with a gain-of-function resulting in either constitutive activation of the relevant molecule and/or enhanced sensitivity for endogenous ligands.

We make the point here that different treatment strategies are implied according to pathological mechanism relevant to the type I interferonopathy being considered ([Fig. 3](#fig3){ref-type="fig"}). Thus, based on the hypothesis that type I interferon might, in certain AGS-related genotypes, be induced by cytosolic recognition of DNA derived from endogenous retroelements ([@bib88]; [@bib9]), we are currently running the first ever clinical trial in AGS, using reverse transcription inhibitors (<https://clinicaltrials.gov/ct2/show/NCT02363452>). From a practical perspective, even if the precise nature of the interferon-inducing signal remains unclear in all cases, success in defining the signaling pathways involved in certain genotypes is already informing potential therapeutic strategies. Thus, as indicated in mice, inhibition of cGAS or STING would be predicted as relevant for TREX1- and RNASEH2-related disease ([@bib40]; [@bib41]; [@bib43]; [@bib64]; [@bib74]), but not for disease consequent upon mutations in *ADAR1* ([@bib60]; [@bib72]) or *IFIH1* ([@bib39]). We note recent work suggesting that antimalarial drugs such as hydroxychloroquine could be beneficial in this context, by antagonizing dsDNA stimulation of cGAS ([@bib6]). In contrast, TBK1 inhibition might be relevant to mutant genotypes induced by either DNA or RNA ([@bib45]). Notably, crossing of the Trex1-null mouse with mice heterozygous for any of cGAS, Tmem173, or Irf3 significantly ameliorates the otherwise lethal phenotype. Similarly, crossing the ENU gain-of-function Mda5 mutant with a Mavs heterozygote was associated with a marked reduction in the severity of the associated nephritis. These data are important in suggesting a degree of "suppleness" in the response to pathological signaling. That is, they indicate that future therapies blocking these molecules might demonstrate clinical efficacy at doses that may not entail iatrogenic immunodeficiency consequent upon loss of signaling to viral nucleic acids. Perhaps relevant to this point also, our experience with JAK1/2 inhibition, see below, has so far been notable by the absence of an increased risk of infection.

![**Outline of treatment strategies in the type I interferonopathies.** Dependent on the underlying pathological mechanism, therapeutic approaches in the type I interferonopathies might include blocking the generation (e.g., using reverse transcription inhibitors: <https://clinicaltrials.gov/ct2/show/NCT02363452>), sensing (e.g., cGAS inhibition by hydroxychloroquine \[[@bib6]\]), or signaling (e.g., TBK1 inhibition \[[@bib45]\]) of putative self--nucleic acids engaging the type I interferon innate immune machinery and blocking of interferon itself (e.g., with anti--type I interferon antibodies), the IFNAR receptor, or the signaling cascades distal to interferon ligand binding (e.g., by JAK1 inhibition \[[@bib38]\]).](JEM_20161596_Fig3){#fig3}

As postulated here, all type I interferonopathy pathology converges on up-regulated type I interferon signaling. Thus, any compounds that neutralize type I interferons, block the type I interferon receptor, or inhibit signaling downstream of the receptor might be of utility. Currently, no drugs are specifically licensed for any member of the type I interferonopathy grouping. We have recently described the effect of JAK1/2 inhibition using ruxolitinib in the context of mutations in *TMEM173*, where we observed highly promising efficacy in all aspects of the clinical phenotype (systemic inflammation, destructive skin lesions, and pulmonary disease; [@bib38]). The same may also be true of proteasome-associated autoinflammatory syndromes ([@bib49]). Anti-interferon therapy is being actively pursued in the treatment of SLE ([@bib94]; [@bib69]), with antibodies against the type I interferon receptor showing particular promise. We have not been able to test these molecules in any monogenic interferonopathy. Interestingly, inactivated interferon α 2b coupled to a carrier protein can induce the production of a polyclonal antibody response against all 13 subtypes of interferon α, and a reduction of the associated interferon signature in high responders to vaccination ([@bib35]). These data link nicely with those showing that patients with mutations in *AIRE* produce endogenous antibodies against all interferon α subtypes, but not interferon β, γ, or λ ([@bib67]). Despite the remarkably high affinity of these antibodies, considerably greater than those used in commercial trials, these patients do not suffer an increased burden of viral infection, perhaps because they maintain antiviral protection through interferon β. If it can be shown that any type I interferonopathy relates predominately/exclusively to interferon α, the therapeutic use of such antibodies might prove highly effective.

Finally, we highlight uncertainty regarding the cellular source of type I interferon production in distinct type I interferonopathies. Early data from the Trex1-null mouse indicated the importance of tissue-resident cells in disease pathology ([@bib88]), whereas more recent papers have emphasized a role for hematopoietic cells in driving disease ([@bib2]; [@bib71]). The latter results are important in pointing to a lack of current knowledge relating to the efficacy of bone marrow transplant in any of the type I interferonopathies. Allied to this issue is the question of which cell types drive the brain involvement characteristic of the majority of type I interferonopathies so far identified ([@bib31]; [@bib42]) and of blood--brain barrier penetration in regards to drug therapy.

Conclusion {#s09}
==========

There has been a rapid adoption of the type I interferonopathy paradigm, with the definition of 10 associated genotypes since the introduction of the term into the medical lexicon in 2011. The study of the monogenic type I interferonopathies provides an unprecedented opportunity to define the role of type I interferons in human health and disease---through the identification of patients showing discrete molecular perturbation of proteins essential to interferon homeostasis. The model outlined here predicts that such studies will be of real clinical value as therapies to reduce type I interferon levels and/or block interferon signaling become available.
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